These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 27727520

  • 1. The therapeutic landscape of non-alcoholic steatohepatitis.
    Perazzo H, Dufour JF.
    Liver Int; 2017 May; 37(5):634-647. PubMed ID: 27727520
    [Abstract] [Full Text] [Related]

  • 2. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
    Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA, Nonalcoholic Steatohepatitis Clinical Research Network.
    Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
    [Abstract] [Full Text] [Related]

  • 3. [Pharmacological treatment of NASH].
    Serfaty L.
    Presse Med; 2019 Dec; 48(12):1489-1495. PubMed ID: 31757735
    [Abstract] [Full Text] [Related]

  • 4. [Treatment of non-alcoholic fatty liver disease].
    Heebøll S, Vilstrup H, Grønbæk H.
    Ugeskr Laeger; 2018 Jul 30; 180(31):. PubMed ID: 30064623
    [Abstract] [Full Text] [Related]

  • 5. [Treatment Options in Non-alcoholic Fatty Liver Disease].
    Kim W.
    Korean J Gastroenterol; 2017 Jun 25; 69(6):353-358. PubMed ID: 28637104
    [Abstract] [Full Text] [Related]

  • 6. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
    Said A, Akhter A.
    Ann Hepatol; 2017 Jun 25; 16(4):538-547. PubMed ID: 28611274
    [Abstract] [Full Text] [Related]

  • 7. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM, Sanyal AJ.
    Liver Int; 2017 Jan 25; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [Abstract] [Full Text] [Related]

  • 8. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M.
    World J Gastroenterol; 2018 Jan 14; 24(2):179-194. PubMed ID: 29375204
    [Abstract] [Full Text] [Related]

  • 9. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A, GOLDEN-505 Investigator Study Group.
    Gastroenterology; 2016 May 14; 150(5):1147-1159.e5. PubMed ID: 26874076
    [Abstract] [Full Text] [Related]

  • 10. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
    Corey KE, Rinella ME.
    Dig Dis Sci; 2016 May 14; 61(5):1387-97. PubMed ID: 26942734
    [Abstract] [Full Text] [Related]

  • 11. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Golabi P, Bush H, Younossi ZM.
    Clin Liver Dis; 2017 Nov 14; 21(4):739-753. PubMed ID: 28987260
    [Abstract] [Full Text] [Related]

  • 12. Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis.
    Tølbøl KS, Stierstorfer B, Rippmann JF, Veidal SS, Rigbolt KTG, Schönberger T, Gillum MP, Hansen HH, Vrang N, Jelsing J, Feigh M, Broermann A.
    Dig Dis Sci; 2019 May 14; 64(5):1238-1256. PubMed ID: 30511198
    [Abstract] [Full Text] [Related]

  • 13. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Gawrieh S, Chalasani N.
    Clin Liver Dis; 2018 Feb 14; 22(1):189-199. PubMed ID: 29128056
    [Abstract] [Full Text] [Related]

  • 14. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, Munda P, Trauner M.
    Dig Dis; 2015 Feb 14; 33(4):598-607. PubMed ID: 26159280
    [Abstract] [Full Text] [Related]

  • 15. Reversal of NASH fibrosis with pharmacotherapy.
    Alukal JJ, Thuluvath PJ.
    Hepatol Int; 2019 Sep 14; 13(5):534-545. PubMed ID: 31363910
    [Abstract] [Full Text] [Related]

  • 16. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y, Sugimoto K, Inui H, Fukusato T.
    World J Gastroenterol; 2015 Apr 07; 21(13):3777-85. PubMed ID: 25852263
    [Abstract] [Full Text] [Related]

  • 17. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.
    Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Unalp A, Tonascia J, NASH CRN Research Group.
    Contemp Clin Trials; 2009 Jan 07; 30(1):88-96. PubMed ID: 18804555
    [Abstract] [Full Text] [Related]

  • 18. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
    Caldwell S.
    Clin Mol Hepatol; 2017 Jun 07; 23(2):103-108. PubMed ID: 28494529
    [Abstract] [Full Text] [Related]

  • 19. Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence.
    Tang JT, Mao YM.
    J Dig Dis; 2017 Nov 07; 18(11):607-617. PubMed ID: 29106066
    [Abstract] [Full Text] [Related]

  • 20. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K.
    Diabetologia; 2016 Jun 07; 59(6):1112-20. PubMed ID: 27101131
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.